{"title":"Oncology - Genetic Testing and Care Services","description":"","products":[{"product_id":"egcanall","title":"Comprehensive Cancer Panel","description":"The Comprehensive Cancer Panel analyzes 109 genes associated with hereditary cancers across major organ systems, including:\n\n\nbreast and gynecologic (breast, ovarian, uterine)\ngastrointestinal (colorectal, gastric, pancreatic)\nendocrine (thyroid, paraganglioma\/pheochromocytoma, parathyroid, pituitary)\ngenitourinary (renal\/urinary tract, prostate)\nskin (melanoma, basal cell carcinoma)\nbrain\/nervous system\nsarcoma\nhematologic (myelodysplastic syndrome\/leukemia)\n\nThe Comprehensive Cancer Panel is designed to maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting multiple organ systems. \n\n\nGenetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. Heterozygous Pathogenic\/Likely pathogenic germline variants in RAD50 and NBN are not clearly associated with an increased risk for cancer; however, such variants may qualify certain patients for clinical trials targeting homologous recombination deficient tumors. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150025502,"sku":"EGCANALL","price":2300.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcanbov","title":"Breast and Ovarian Cancer Panel","description":"The Breast and Ovarian Cancer Panel analyzes genes that are associated with hereditary predisposition to breast, ovarian, and endometrial\/uterine cancers. The genetic heterogeneity associated with these conditions can make it difficult to use phenotype as the sole criterion to select a definitive cause. These genes were curated based on the available evidence to date in order to provide analysis for hereditary breast and gynecologic cancers. Given the clinical overlap of hereditary susceptibility to breast and gynecologic cancers, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. Some genes in this test may also be associated with additional unrelated disorders, which are not included in the list of disorders tested. Genetic testing of these genes may help confirm a clinical diagnosis, help predict disease prognosis and progression, facilitate early detection of symptoms, inform family planning and genetic counseling, or promote enrollment in clinical trials.","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150058270,"sku":"EGCANBOV","price":2550.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcancrc","title":"Colorectal Cancer Panel","description":"The Colorectal Cancer Panel analyzes genes associated with a hereditary predisposition to colorectal cancer. These genes were selected based on the available evidence to date to provide the broadest test for colorectal cancer.\n\nIn addition to the primary panel, several genes have been included to cover preliminary evidence for cancer predisposition. These genes were selected from a review of the literature and expert recommendations. \nGenetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150091038,"sku":"EGCANCRC","price":2550.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-intestine-v1.png?v=1793570970"},{"product_id":"egcanlun","title":"Lung Cancer Panel","description":"The Lung Cancer Panel analyzes genes that are associated with hereditary predispositions to lung cancers. The genetic heterogeneity associated with these conditions can make it difficult to use phenotype as the sole criterion to select a definitive cause. These genes were curated based on the available evidence to date in order to provide analysis for hereditary lung cancers. Given the clinical overlap of various cancer phenotypes, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. Some genes in this test may also be associated with additional unrelated disorders, which are not included in the list of disorders tested. Genetic testing of these genes may help confirm a clinical diagnosis, help predict disease prognosis and progression, facilitate early detection of symptoms, inform family planning and genetic counseling, or promote enrollment in clinical trials.","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150123806,"sku":"EGCANLUN","price":2550.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-lungs-v1.png?v=1793570976"},{"product_id":"egcangas","title":"Gastric Cancer Panel","description":"The Gastric Cancer Panel analyzes genes associated with an increased lifetime risk of developing stomach cancer. These genes were selected based on the available evidence to date to provide the broadest hereditary gastric cancer test. Many of these genes are also associated with an increased risk of other cancer types.\nGenetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150156574,"sku":"EGCANGAS","price":2550.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-stomach-v1.png?v=1793570983"},{"product_id":"egcanpan","title":"Pancreatic Cancer Panel","description":"The Pancreatic Cancer Panel analyzes genes that are associated with a hereditary predisposition for pancreatic cancer. These genes were selected based on the available evidence to date to provide the broadest test for hereditary pancreatic cancer. \nGenetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150189342,"sku":"EGCANPAN","price":2550.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-pancreas-v1.png?v=1793570990"},{"product_id":"egcanskn","title":"Melanoma\/Skin Cancer Panel","description":"The Melanoma\/Skin Cancer Panel analyzes genes associated with a hereditary predisposition to melanoma. These genes were selected based on available evidence to provide the most comprehensive test targeting hereditary melanoma. Given the clinical overlap of hereditary susceptibility to skin cancers, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. \nGenetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150222110,"sku":"EGCANSKN","price":2550.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-skin-v1.png?v=1793570996"},{"product_id":"egcanpca","title":"Prostate Cancer Panel","description":"The Prostate Cancer Panel analyzes genes associated with a hereditary predisposition to prostate cancer. These genes were selected based on the available evidence to date to provide the most comprehensive test for hereditary prostate cancer. Given the clinical overlap of hereditary susceptibility to prostate cancer, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. \n\nGenetic testing may confirm a clinical diagnosis and guide treatment and management decisions. At-risk relatives may also be identified, allowing the pursuit of a diagnostic evaluation, early detection, and improved clinical outcome. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150254878,"sku":"EGCANPCA","price":2300.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-cell-v1.png?v=1793571004"},{"product_id":"egcanend","title":"Endometrial Cancer Panel","description":"The Endometrial Cancer Panel analyzes genes associated with a hereditary predisposition to endometrial cancer. These genes were selected based on the available evidence to date to provide the most comprehensive test for hereditary endometrial cancer. Given the clinical overlap of hereditary susceptibility to endometrial cancer, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. \n\nGenetic testing may confirm a clinical diagnosis and guide treatment and management decisions. At-risk relatives may also be identified, allowing the pursuit of a diagnostic evaluation, early detection, and improved clinical outcome. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150320414,"sku":"EGCANEND","price":2550.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-uterus-v1.png?v=1793571011"},{"product_id":"egcanped","title":"Pediatric Cancer Panel","description":"The Pediatric Cancer Panel analyzes genes that are associated with the development of malignant and benign tumors throughout the body. The genetic heterogeneity associated with these conditions can make it difficult to use phenotype as the sole criterion to select a definitive cause. These genes were curated based on the available evidence to date in order to provide analysis for hereditary predisposition to childhood solid tumors. Given the clinical overlap of pediatric solid tumors, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. Some genes in this test may also be associated with additional unrelated disorders, which are not included in the list of disorders tested. \n\nGenetic testing of these genes may help confirm a clinical diagnosis, predict disease prognosis and progression, facilitate early detection of symptoms, inform family planning and genetic counseling, or promote enrollment in clinical trials.","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150385950,"sku":"EGCANPED","price":2300.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-baby-v1.png?v=1793571061"},{"product_id":"egcansom","title":"Comprehensive Tumor Profiling","description":"The Comprehensive Tumor Profiling offers comprehensive genomic profiling for solid tumors using a sequencing (NGS)-based assay that analyzes 484 genes for clinically important alterations at the DNA level. This test interrogates the complete coding regions of 468 genes and the introns of 43 genes for all four types of genomic abnormalities: SNV, InDel, CNV and fusion. These genes are known to be relevant for the diagnosis and\/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) Guidelines and the medical literature. The mutation status of some of these genes can guide the potential application of multiple FDA-approved targeted and\/or immunotherapies as shown Diseases Tested list. The other genes are also analyzed for their relevance to the diagnosis and\/or treatment of various solid tumors according to the medical literature. The report generated provides tailored treatment recommendations for your patients. This test should be used to analyze solid tumors only and has not been optimized for hematological malignancies. \n\nThe clinical interpretation of detected mutations in those genes is done according to our comprehensive in-house oncology knowledgebase constructed based on public resources including GeneCards, CKB, OncoKB, COSMIC, ClinVar PMC, Drugs@FDA, Drug Information Portal (NIH), Selleck, PharmGKB, DGIdb, DRUGBANK, Drugs.com, ClinicalTrials.gov, ICTRP, ChiCTR, KEGG and Cell Signaling. \n\nLimit of Detection (LOD):\nThe LoD of SNV\/InDel detection is 1% mutation allele frequency (MAF) for tissue samples (detection rate = 96.6%) and 0.5% MAF for ctDNA samples (detection rate = 100%).\nThe LoD of ERBB2 CNV detection is 20% tumor cell content for tissue samples (detection rate = 100%) and 5% tumor cell content for ctDNA samples (detection rate = 100%).\nThe LoD of ROS1 and ALK fusion detection is 20% tumor cell content for tissue samples (detection rate = 100%) and 1.25% tumor cell content for ctDNA samples (detection rate = 100%).\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150418718,"sku":"EGCANSOM","price":4950.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-cell-v1.png?v=1793571004"},{"product_id":"egcancfd","title":"Comprehensive cfDNA Profiling","description":"Comprehensive cfDNA Profiling offers comprehensive genomic profiling for solid tumors using a sequencing (NGS)-based assay that analyzes 484 genes for clinically important alterations at the DNA level. This test interrogates the complete coding regions of 468 genes and the introns of 43 genes for all four types of genomic abnormalities: SNV, InDel, CNV and fusion and also generate results (TMB, bTMB and MSI) that can help guide clinical management. These genes are known to be relevant for the diagnosis and\/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) Guidelines and the medical literature. The mutation status of some of these genes can guide the potential application of multiple FDA-approved targeted and\/or immunotherapies as shown Diseases Tested list. The other genes are also analyzed for their relevance to the diagnosis and\/or treatment of various solid tumors according to the medical literature. The report generated provides tailored treatment recommendations for your patients. This test should be used to analyze solid tumors only and has not been optimized for hematological malignancies. \n\nThe clinical interpretation of detected mutations in those genes is done according to our comprehensive in-house oncology knowledgebase constructed based on public resources including GeneCards, CKB, OncoKB, COSMIC, ClinVar PMC, Drugs@FDA, Drug Information Portal (NIH), Selleck, PharmGKB, DGIdb, DRUGBANK, Drugs.com, ClinicalTrials.gov, ICTRP, ChiCTR, KEGG and Cell Signaling. \n\n\nLimit of Detection (LOD):\nThe LoD of SNV\/InDel detection is 1% mutation allele frequency (MAF) for tissue samples (detection rate = 96.6%) and 0.5% MAF for ctDNA samples (detection rate = 100%).\nThe LoD of ERBB2 CNV detection is 20% tumor cell content for tissue samples (detection rate = 100%) and 5% tumor cell content for ctDNA samples (detection rate = 100%).\nThe LoD of ROS1 and ALK fusion detection is 20% tumor cell content for tissue samples (detection rate = 100%) and 1.25% tumor cell content for ctDNA samples (detection rate = 100%).\n\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974150451486,"sku":"EGCANCFD","price":4950.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-drop-v1.png?v=1793571068"},{"product_id":"egcanbrc","title":"BRCA1 \u0026 BRCA2 Hereditary","description":"\u003cp\u003eBRCA1 \u0026amp; BRCA2 Hereditary\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790439805214,"sku":"EGCANBRC","price":1800.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcancan","title":"CanAssist Breast","description":"\u003cp\u003eCanAssist Breast\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790439837982,"sku":"EGCANCAN","price":6300.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcanctp","title":"Customized Tumor Profiling","description":"\u003cp\u003ehe Comprehensive Tumor Profiling offers comprehensive genomic profiling for solid tumors using a sequencing (NGS)-based assay that analyzes 10 Genes for clinically important alterations at the DNA level. This test interrogates the customized coding regions of 10 Genes for all four types of genomic abnormalities: SNV, InDel, CNV, and fusion. These Genes are known to be relevant for the diagnosis and\/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) Guidelines and the medical literature. The mutation status of some of these Genes can guide the potential application of multiple FDA-approved targeted and\/or immunotherapies as shown Diseases Tested list. The other Genes are also analyzed for their relevance to the diagnosis and\/or treatment of various solid tumors according to the medical literature. The report generated provides tailored treatment recommendations for your patients. This test should be used to analyze solid tumors only and has not been optimized for hematological malignancies.\u003c\/p\u003e\u003cp\u003eThe clinical interpretation of detected mutations in those Genes is done according to our comprehensive in-house oncology knowledgebase constructed based on public resources including GeneCards, CKB, OncoKB, COSMIC, ClinVar PMC, Drugs@FDA, Drug Information Portal (NIH), Selleck, PharmGKB, DGIdb, DRUGBANK, Drugs.com, ClinicalTrials.gov, ICTRP, ChiCTR, KEGG and Cell Signaling.\u003c\/p\u003e\u003cp\u003eLimit of Detection (LOD):\u003c\/p\u003e\u003cp\u003eThe LoD of SNV\/InDel detection is 1% mutation allele frequency (MAF) for tissue samples (detection rate = 96.6%) and 0.5% MAF for ctDNA samples (detection rate = 100%).\u003c\/p\u003e\u003cp\u003eThe LoD of ERBB2 CNV detection is 20% tumor cell content for tissue samples (detection rate = 100%) and 5% tumor cell content for ctDNA samples (detection rate = 100%).\u003c\/p\u003e\u003cp\u003eThe LoD of ROS1 and ALK fusion detection is 20% tumor cell content for tissue samples (detection rate = 100%) and 1.25% tumor cell content for ctDNA samples (detection rate = 100%).\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790439903518,"sku":"EGCANCTP","price":3050.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcanhrr","title":"HRR (Homologous Recombination Repair) Cancer Gene panel","description":"\u003cp\u003eThis panel is used to analyze mutations in genes involved in the homologous recombination repair (HRR) pathway—a critical mechanism for maintaining DNA stability. Mutations in these genes are associated with increased cancer susceptibility and can predict therapeutic response to agents like PARP inhibitors and platinum-based chemotherapies.\u003c\/p\u003e\u003cp\u003eThe test is suitable only for germline (hereditary cancer risk assessment).\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790440427806,"sku":"EGCANHRR","price":2000.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcanpdl","title":"PDL1 immunostaining","description":"\u003cp\u003ePDL1 immunostaining\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790440493342,"sku":"EGCANPDL","price":1500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcanren","title":"Hereditary Renal Cancer Panel","description":"\u003cp\u003eThis panel includes genes such as VHL, MET, and FH, which are involved in cellular metabolism and tumor suppression. Pathogenic variants in these genes can predispose individuals to various types of renal cancers, including clear cell renal cell carcinoma and papillary renal cell carcinoma. • The test provides critical information for healthcare providers to offer personalized risk assessments, tailored screening recommendations, and potential targeted treatment options for those at risk or diagnosed with hereditary renal cancers\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790440526110,"sku":"EGCANREN","price":2200.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-kidneys-v1.png?v=1793571473"},{"product_id":"egcanrna","title":"Comprehensive Tumor Profiling – RNA","description":"\u003cp\u003eComprehensive Tumor Profiling (RNA) is a next-generation sequencing (NGS)-based assay that evaluates the RNA expression profile of tumor samples to provide a deeper understanding of tumor biology. Unlike DNA-based testing, RNA profiling focuses on active gene expression, enabling detection of gene fusions, splice variants, and transcriptional changes that may not be visible at the DNA level.\u003c\/p\u003e\u003cp\u003eThis test is widely used in oncology to identify actionable biomarkers that guide targeted therapy selection, immunotherapy decisions, and clinical trial eligibility. It is particularly valuable for detecting gene fusions in solid tumors and hematologic malignancies, as well as assessing pathway activation that may influence tumor behavior and treatment response.\u003c\/p\u003e\u003cp\u003eThe results provide clinicians with a comprehensive molecular overview of the tumor, supporting precision oncology and personalized treatment strategies.\u003c\/p\u003e\u003cp\u003eClinical Applications\u003cbr\u003eDetection of gene fusions and rearrangements\u003cbr\u003eDepending on the panel, RNA tumor profiling may detect fusions such as:\u003c\/p\u003e\u003cp\u003eALK fusions (e.g., EML4-ALK in lung cancer)\u003cbr\u003eROS1 fusions (lung cancer)\u003cbr\u003eRET fusions (lung, thyroid cancers)\u003cbr\u003eNTRK1\/2\/3 fusions (multiple solid tumors)\u003cbr\u003eFGFR fusions (bladder, cholangiocarcinoma)\u003cbr\u003eBCR-ABL1 fusion (CML – hematologic malignancy)\u003cbr\u003ePML-RARA fusion (acute promyelocytic leukemia)\u003cbr\u003eEWSR1 fusions (sarcomas)\u003c\/p\u003e\u003cp\u003eIdentification of actionable RNA biomarkers\u003cbr\u003eTumor classification and molecular subtyping\u003cbr\u003eTherapy selection (targeted therapy \u0026amp; immunotherapy)\u003cbr\u003eClinical trial matching\u003cbr\u003eComplementary analysis to DNA-based tumor profiling\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790440558878,"sku":"EGCANRNA","price":4650.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egcansomr","title":"Comprehensive Tumor Profiling (DNA-RNA)","description":"\u003cp\u003eComprehensive Tumor Profiling (DNA–RNA) is an advanced Next-Generation Sequencing (NGS)–based assay designed to provide a broad molecular characterization of solid tumors. The test simultaneously analyzes 562 cancer-related genes at the DNA level and 100 genes at the RNA level to detect multiple classes of genomic alterations that may drive tumor development, progression, and treatment response.\u003c\/p\u003e\u003cp\u003eThe DNA component of the assay identifies a wide spectrum of genomic variants, including single nucleotide variants (SNVs), small insertions and deletions (indels), copy number variations (CNVs), and structural alterations across key oncogenes and tumor suppressor genes. This analysis enables the detection of clinically relevant mutations that may be associated with targeted therapies, prognostic implications, or resistance mechanisms.\u003c\/p\u003e\u003cp\u003eThe RNA component focuses on the detection of gene fusions and rearrangements, which are important oncogenic drivers in many cancers. RNA sequencing allows for the identification of fusion transcripts involving critical genes such as ALK, ROS1, RET, NTRK, and others, which may not always be detected reliably at the DNA level. By analyzing gene expression and fusion events, RNA sequencing improves the overall sensitivity for detecting therapeutically actionable alterations.\u003c\/p\u003e\u003cp\u003eBy integrating both DNA and RNA analysis, Comprehensive Tumor Profiling offers a more complete understanding of the tumor’s molecular landscape compared with DNA-only testing. The results provide clinicians with valuable information regarding actionable biomarkers, eligibility for targeted therapies, potential immunotherapy markers, and suitability for relevant clinical trials.\u003c\/p\u003e\u003cp\u003eThis test is typically performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue, The comprehensive molecular insights generated by this test support precision oncology approaches, enabling more informed and personalized treatment strategies for cancer patients\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790440853790,"sku":"EGCANSOMR","price":6500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsombil","title":"Biliary Tract Cancer Panel","description":"\u003cp\u003eThe Biliary Tract Cancer Panel (Somatic) NGS is a comprehensive genetic testing panel designed to identify key genetic alterations in biliary tract cancers, which include gallbladder cancer, cholangiocarcinoma, and ampullary cancers. This test analyzes 8 critical genes and biomarkers involved in the development and progression of these cancers:\u003c\/p\u003e\u003cp\u003eNTRK genes (NTRK1, NTRK2, NTRK3)\u003cbr\u003eBRAF V600E mutation\u003cbr\u003eFGFR2 fusion\u003cbr\u003eIDH1 mutation\u003cbr\u003eRET gene fusion\u003cbr\u003eKRAS G12C mutation\u003cbr\u003eAdditionally, the panel evaluates Microsatellite Instability (MSI), Tumor Mutational Burden (TMB), and Deficient Mismatch Repair (DMMR), which are important biomarkers for immunotherapy eligibility and personalized treatment strategies.\u003c\/p\u003e\u003cp\u003eThis panel provides valuable insights into the genetic makeup of biliary tract tumors, helping physicians select targeted therapies, understand prognosis, and make informed decisions regarding the patient’s care plan.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790446031134,"sku":"EGSOMBIL","price":3200.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsombosq","title":"Somatic Breast and Ovarian Cancer Panel (Sequencing Only)","description":"\u003cp\u003eThis test analyzes tumor DNA to identify somatic (non-inherited) mutations in genes associated with breast and ovarian cancer. It uses next-generation sequencing (NGS) to detect genetic alterations that may guide diagnosis, prognosis, and targeted therapy decisions. This panel does not assess inherited (germline) mutations.\u003cbr\u003eThe data will be delivered in its raw format, typically as FASTQ or VCF files, for further analysis by researchers, bioinformaticians, or laboratories. This option is suitable for users who wish to conduct their own detailed analysis or who do not require a clinical report.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790446358814,"sku":"EGSOMBOSQ","price":2400.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsombrc","title":"Somatic Breast and Ovarian Cancer Panel","description":"\u003cp\u003eThese cancers are among the most common in women, and this panel helps in understanding their genetic underpinnings. By identifying key mutations, it supports the development of effective treatment strategies. Comprehensive genetic profiling improves patient outcomes and supports better disease management.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790446391582,"sku":"EGSOMBRC","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsomcol","title":"Somatic Colorectal Cancer Panel","description":"\u003cp\u003eThis panel serves as a vital tool in molecular diagnostic testing of colorectal cancer patients. By analyzing genetic alterations specific to colorectal cancer tumors, this panel offers critical insights that guide treatment decisions and prognosis for patients diagnosed with this disease.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790446719262,"sku":"EGSOMCOL","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-intestine-v1.png?v=1793570970"},{"product_id":"egsomhrr","title":"HRR (Homologous Recombination Repair) Somatic Gene Panel","description":"\u003cp\u003eThis panel is used to analyze mutations in genes involved in the homologous recombination repair (HRR) pathway—a critical mechanism for maintaining DNA stability. Mutations in these genes are associated with increased cancer susceptibility and can predict therapeutic response to agents like PARP inhibitors and platinum-based chemotherapies.\u003c\/p\u003e\u003cp\u003eThe test is suitable for somatic (tumor tissue profiling) analysis.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447374622,"sku":"EGSOMHRR","price":3050.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsomlun","title":"Somatic Lung Cancer Panel","description":"\u003cp\u003eThis panel provides critical information for targeted therapies and personalized treatment approaches. By identifying key genetic changes, it supports the development of effective treatment strategies. Comprehensive genetic profiling enhances clinical outcomes and supports better management of lung cancer\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447407390,"sku":"EGSOMLUN","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-lungs-v1.png?v=1793570976"},{"product_id":"egsommela","title":"Somatic Melanoma Cancer Panel","description":"\u003cp\u003eThis panel supports the identification of targeted therapies and helps in understanding the genetic basis of this aggressive cancer. By providing a detailed genetic profile, this panel aids in the development of personalized treatment plans. Early detection of mutations improves treatment outcomes and patient prognosis.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447767838,"sku":"EGSOMMELA","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-skin-v1.png?v=1793570996"},{"product_id":"egsomner","title":"Somatic Central Nervous System (CNS) Cancer Panel","description":"\u003cp\u003eThis panel provides a detailed genetic profile witch aids in the selection of personalized therapies and enhances our understanding of tumor behavior. This comprehensive analysis is crucial for improving clinical outcomes in neurological cancer patients.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447800606,"sku":"EGSOMNER","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsompanc","title":"Somatic Pancreatic Cancer Panel","description":"\u003cp\u003eBy identifying actionable mutations, this panel aids in the development of targeted therapy strategies and personalized treatment plans. It helps in understanding the molecular mechanisms driving the disease, offering insights that can improve patient outcomes. Early detection of genetic changes allows for timely intervention and better management of pancreatic cancer.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447833374,"sku":"EGSOMPANC","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-pancreas-v1.png?v=1793570990"},{"product_id":"egsompros","title":"Somatic Prostate Cancer Panel","description":"\u003cp\u003eThis panel offers valuable insights into tumor biology, facilitating personalized treatment strategies and improving disease management. By identifying mutations that drive tumor growth, it helps in tailoring therapies that are more effective for individual patients. This targeted approach enhances treatment outcomes and supports ongoing monitoring of disease progression.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447898910,"sku":"EGSOMPROS","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-cell-v1.png?v=1793571004"},{"product_id":"egsomren","title":"Somatic Renal Cancer Panel","description":"\u003cp\u003eThis panel aids in the diagnosis, prognosis, and selection of targeted therapies for kidney cancer patients. By identifying genetic changes that drive tumor growth, it supports personalized treatment approaches. Comprehensive genetic profiling is essential for improving clinical outcomes and managing renal cancer effectively.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447964446,"sku":"EGSOMREN","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-kidneys-v1.png?v=1793571473"},{"product_id":"egsomret","title":"Somatic Retinoblastoma Cancer Panel","description":"\u003cp\u003eThis panel aids in early diagnosis, risk assessment, and personalized treatment planning for this serious condition. By providing a detailed genetic analysis, this panel supports timely therapeutic interventions. Understanding the genetic factors driving retinoblastoma enhances treatment effectiveness and patient prognosis.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790447997214,"sku":"EGSOMRET","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsomrsar","title":"Somatic Rhabdomyosarcoma Cancer Panel","description":"\u003cp\u003eThis panel aids in the diagnosis, prognosis, and personalized treatment planning for this challenging pediatric cancer. By identifying mutations that drive tumor growth, it helps in tailoring therapies to individual patients. This targeted approach enhances treatment effectiveness and supports better disease management.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790448062750,"sku":"EGSOMRSAR","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsomsarc","title":"Somatic Sarcoma Cancer Panel","description":"\u003cp\u003eThis panel identifies mutations that can inform treatment decisions and improve patient management in these complex tumors. By understanding the genetic underpinnings of sarcomas, this panel supports personalized therapy strategies. Comprehensive genetic insights are crucial for enhancing treatment outcomes and patient care.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790448193822,"sku":"EGSOMSARC","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-ribbon-v1.png?v=1793570962"},{"product_id":"egsomstom","title":"Somatic Stomach Cancer Panel","description":"\u003cp\u003eThis panel enables precise molecular characterization of tumors, guiding the selection of effective treatment options and monitoring disease progression. By identifying key genetic changes, this panel supports personalized medicine approaches that can improve patient outcomes. Early detection of mutations allows for timely therapeutic interventions and better management of gastric cancer.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790448226590,"sku":"EGSOMSTOM","price":3250.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-oncology-stomach-v1.png?v=1793570983"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/collections\/icon-oncology.png?v=1685834430","url":"https:\/\/shop.enigmagenomics.com\/en\/collections\/oncology.oembed?page=4","provider":"Enigma Genomics","version":"1.0","type":"link"}